Industry 4.0. Artificial intelligence. Big data. Even continuous manufacturing. All of these new technologies will drive the future of pharmaceutical and biopharmaceutical manufacturing. Yet questions persist as to how the U.S. FDA and other global regulatory agencies will address these new technologies, leaving some companies reluctant to fully embrace these advances as early adopters.